|
WO2021067389A1
|
|
Lentiviral vector formulations
|
|
WO2020257462A1
|
|
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
|
US2020199626A1
|
|
Use of lentiviral vectors expressing factor ix
|
|
AU2019319984A1
|
|
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
KR20210020030A
|
|
How to treat hemophilia A
|
|
KR20200118089A
|
|
Use of lentiviral vectors expressing factor VIII
|
|
CN111247251A
|
|
Nucleic acid molecules and uses thereof
|
|
AU2018215092A1
|
|
Factor IX fusion proteins and methods of making and using same
|
|
CA3044838A1
|
|
Methods of inducing immune tolerance to clotting factors
|
|
BR112019011115A2
|
|
methods for treating hemophilic arthropathy using chimeric clotting factors
|
|
WO2018098363A2
|
|
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
CA3012695A1
|
|
Optimized factor viii genes
|
|
AU2016244273A1
|
|
Immunoglobulin Chimeric Monomer-Dimer Hybrids
|
|
KR20180029262A
|
|
Factor IX fusion proteins and methods for their manufacture and use
|
|
EP3033097A2
|
|
Factor viii-xten fusions and uses thereof
|
|
US2016185817A1
|
|
Purification of chimeric FVIII molecules
|
|
US2014308280A1
|
|
Factor VIII polypeptide formulations
|
|
EP2956477A1
|
|
Optimized factor viii gene
|
|
US2016296607A1
|
|
Methods of using a fixed dose of a clotting factor
|
|
AU2013245463A1
|
|
Immunoglobulin Chimeric Monomer-Dimer Hybrids
|
